Navigation Links
ULURU Inc. Announces Conference Call
Date:11/8/2010

ADDISON, Texas, Nov. 8, 2010 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced that it has scheduled a conference call to discuss the third quarter ended September 30, 2010 financial results and to provide a general business update on Friday, November 12, 2010 at 9:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 23699#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on November 12, 2010 two hours following the end of the call until November 26, 2010 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 for international callers dial (585) 419-6446 (access code 23699#). You may also access the replay of the call two hours following the end of the call until November 26, 2010 at 11:59 p.m. Eastern Time via the web by logging onto http://app.replayrecorder.com/multipoint/.

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For more information about ULURU Inc., please visit www.uluruinc.com. For more information about Altrazeal™, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. GrayPresident & CEOTerry K. WallbergVice President & CFO(214) 905-5145
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Second Quarter 2010 Financial Results
2. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
3. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
5. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
6. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
7. TechniScan, Inc. Announces Restructuring of Convertible Debt
8. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
9. Biotel, Inc. Announces Definitive Merger Agreement With CardioNet, Inc.
10. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
11. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):